DDInter1330 DDInter1763
Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [valsartan], and [irbesartan]. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and synthesis of aldosterone and ADH, cardiac stimulation, and renal reabsorption of sodium, among others. Overall, olmesartan's physiologic effects lead to reduced blood pressure, lower aldosterone levels, reduced cardiac activity, and increased excretion of sodium. Olmesartan also affects the renin-angiotensin aldosterone system (RAAS), which plays an important role in hemostasis and regulation of kidney, vascular, and cardiac functions. Pharmacological blockade of RAAS
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Olmesartan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Olmesartan {u} (Compound) causes {v} (Side Effect) Pharyngitis
Pharyngitis {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Olmesartan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Olmesartan {u} (Compound) causes {v} (Side Effect) Pharyngitis
Pharyngitis {u} (Side Effect) is caused by {v} (Compound) Everolimus
Everolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Olmesartan {u} (Compound) resembles {v} (Compound) Candesartan
Candesartan {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Olmesartan {u} (Compound) resembles {v} (Compound) Candesartan
Candesartan {u} (Compound) downregulates {v} (Gene) NVL
NVL {u} (Gene) is upregulated by {v} (Compound) Temsirolimus
Olmesartan {u} (Compound) resembles {v} (Compound) Azilsartan medoxomil
Azilsartan medoxomil {u} (Compound) causes {v} (Side Effect) Angiopathy
Angiopathy {u} (Side Effect) is caused by {v} (Compound) Temsirolimus
Olmesartan {u} (Compound) resembles {v} (Compound) Candesartan
Candesartan {u} (Compound) upregulates {v} (Gene) TATDN2
TATDN2 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Olmesartan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Temsirolimus
Olmesartan {u} (Compound) resembles {v} (Compound) Azilsartan medoxomil
Azilsartan medoxomil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} (Compound) resembles {v} (Compound) Temsirolimus
Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)
Olmesartan (Compound) causes Pharyngitis (Side Effect) and Pharyngitis (Side Effect) is caused by Temsirolimus (Compound)
Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Olmesartan (Compound) causes Pharyngitis (Side Effect) and Pharyngitis (Side Effect) is caused by Everolimus (Compound) and Everolimus (Compound) resembles Temsirolimus (Compound)
Olmesartan (Compound) resembles Candesartan (Compound) and Candesartan (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Temsirolimus (Compound)
Olmesartan (Compound) resembles Candesartan (Compound) and Candesartan (Compound) downregulates NVL (Gene) and NVL (Gene) is upregulated by Temsirolimus (Compound)
Olmesartan (Compound) resembles Azilsartan medoxomil (Compound) and Azilsartan medoxomil (Compound) causes Angiopathy (Side Effect) and Angiopathy (Side Effect) is caused by Temsirolimus (Compound)
Olmesartan (Compound) resembles Candesartan (Compound) and Candesartan (Compound) upregulates TATDN2 (Gene) and TATDN2 (Gene) is downregulated by Temsirolimus (Compound)
Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Temsirolimus (Compound)
Olmesartan (Compound) resembles Azilsartan medoxomil (Compound) and Azilsartan medoxomil may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus (Compound) resembles Temsirolimus (Compound)